Showing results (121-130 of 149) with videos related to

Sort By:
Pageof 15
Pediatric Blood & Cancer|January 20, 2018
Specific expression of PD-L1 in RELA-fusion supratentorial ependymoma: Implications for PD-1-targeted therapyDavis A Witt, Andrew M Donson, Vladimir Amani, et al.
Marine Pollution Bulletin|December 7, 2010
Cytochrome P4501A biomarker indication of the timeline of chronic exposure of Barrow's goldeneyes to residual Exxon Valdez oilDaniel Esler, Brenda E Ballachey, Kimberly A Trust, et al.
Cancer Immunology Research|May 14, 2015
Interleukin-6/STAT3 Pathway Signaling Drives an Inflammatory Phenotype in Group A EpendymomaAndrea M Griesinger, Rebecca J Josephson, Andrew M Donson, et al.
Oncology Reports|December 6, 2017
Preclinical analysis of MTOR complex 1/2 inhibition in diffuse intrinsic pontine gliomaPatrick C Flannery, John A DeSisto, Vladimir Amani, et al.
Journal of Neuropathology and Experimental Neurology|December 1, 2021
Novel RAF Fusions in Pediatric Low-Grade Gliomas Demonstrate MAPK Pathway ActivationKatherine T Lind, Hannah V Chatwin, John DeSisto, et al.
Environmental Toxicology and Chemistry|September 8, 2010
Cytochrome P4501A biomarker indication of oil exposure in harlequin ducks up to 20 years after the Exxon Valdez oil spillDaniel Esler, Kimberly A Trust, Brenda E Ballachey, et al.
Clinical and Experimental Allergy : Journal of the British Society for Allergy and Clinical Immunology|February 26, 2026
A Pilot Randomised Controlled Dose-Ranging Trial of Ant Venom Immunotherapy With and Without Delta-Inulin AdjuvantThanh-Thao Adriana Le, Troy Wanandy, Griffith B Perkins, et al.
Oncotarget|July 25, 2016
Checkpoint kinase 1 expression is an adverse prognostic marker and therapeutic target in MYC-driven medulloblastomaEric W Prince, Ilango Balakrishnan, Monil Shah, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 26, 2021
Deconvoluting Mechanisms of Acquired Resistance to RAF Inhibitors in BRAFV600E-Mutant Human GliomaKarisa C Schreck, Andrew Morin, Guisheng Zhao, et al.
ESMO Open|May 22, 2025
Phase II study of elraglusib (9-ING-41), a GSK-3β inhibitor, in combination with gemcitabine plus nab-paclitaxel in previously untreated metastatic pancreatic cancerD Mahalingam, A Saeed, S F Powell, et al.
Pageof 15